Hsbc Holdings PLC decreased its stake in shares of Novo Nordisk A/S (NYSE:NVO – Get Rating) by 7.4% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 38,200 shares of the company’s stock after selling 3,047 shares during the period. Hsbc Holdings PLC’s holdings in Novo Nordisk A/S were worth $3,807,000 at the end of the most recent quarter.
A number of other hedge funds have also bought and sold shares of NVO. Worth Asset Management LLC bought a new stake in shares of Novo Nordisk A/S in the first quarter valued at $32,000. Financial Management Professionals Inc. raised its stake in shares of Novo Nordisk A/S by 95.0% during the 3rd quarter. Financial Management Professionals Inc. now owns 312 shares of the company’s stock valued at $31,000 after purchasing an additional 152 shares during the period. Laffer Tengler Investments bought a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at $37,000. Old North State Trust LLC bought a new stake in shares of Novo Nordisk A/S during the 3rd quarter valued at $41,000. Finally, Wagner Wealth Management LLC bought a new stake in shares of Novo Nordisk A/S during the 2nd quarter valued at $57,000. 6.09% of the stock is currently owned by institutional investors.
Wall Street Analyst Weigh In
Several equities analysts recently commented on the company. Credit Suisse Group boosted their target price on Novo Nordisk A/S from 820.00 to 860.00 in a research report on Friday, November 4th. Cowen upped their price objective on Novo Nordisk A/S from $130.00 to $145.00 in a report on Monday, December 12th. Cowen upped their price objective on Novo Nordisk A/S from $130.00 to $145.00 in a report on Monday, December 12th. Finally, JPMorgan Chase & Co. upped their price objective on Novo Nordisk A/S from 925.00 to 1,100.00 and gave the stock an “overweight” rating in a report on Tuesday, January 3rd. One analyst has rated the stock with a sell rating, four have assigned a hold rating, ten have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $697.78.
Novo Nordisk A/S Trading Down 0.9 %
Novo Nordisk A/S Increases Dividend
The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, April 4th. Shareholders of record on Monday, March 27th will be given a dividend of $1.1887 per share. This is a positive change from Novo Nordisk A/S’s previous semi-annual dividend of $0.58. The ex-dividend date is Friday, March 24th. This represents a yield of 0.8%. Novo Nordisk A/S’s dividend payout ratio is presently 23.34%.
About Novo Nordisk A/S
Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases.
Featured Articles
- Get a free copy of the StockNews.com research report on Novo Nordisk A/S (NVO)
- MarketBeat Week in Review – 2/20 – 2/24
- Carvana Skidding On Revenue Decrease, Heavy Debt Burden
- What Are Consumer Staples Stocks?
- Is Rocky Brands Dividend A Good Fit For Your Portfolio?
- Beyond Meat Stock Is Not Beyond Hope
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.
